Savara (SVRA) Interest & Investment Income (2010 - 2026)
Savara (SVRA) posted quarterly Interest & Investment Income of -$247000.0 for Q1 2026, down 60.39% year-over-year from -$623573.8 in Q1 2025, and down 314.78% quarter-over-quarter from $115000.0 in Q4 2025.
Savara (SVRA) Interest & Investment Income (2010 - 2026) Analysis & Trends
Savara (SVRA) has reported Interest & Investment Income for 17 consecutive years, with -$247000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest & Investment Income fell 60.39% year-over-year to -$247000.0; the TTM figure through Mar 2026 stood at -$95000.0 (down 167.38% YoY), while the FY2025 annual figure was -$2000.0, down 104.55% from the prior year.
- Interest & Investment Income fell to -$247000.0 in Q1 2026 per SVRA's latest filing, from $115000.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $583000.0 in Q3 2024 and bottomed at -$263000.0 in Q4 2024.
- Historically, Interest & Investment Income has averaged $2000.0 across 5 years, with a median of -$5000.0 in 2023.
- On a YoY basis, Interest & Investment Income climbed as much as 11760.0% in 2024 and fell as far as 1892.86% in 2024.
- Savara's Interest & Investment Income stood at $29000.0 in 2022, then jumped by 768.97% to $252000.0 in 2023, then tumbled by 204.37% to -$263000.0 in 2024, then soared by 143.73% to $115000.0 in 2025, then plunged by 314.78% to -$247000.0 in 2026.
- Business Quant data shows SVRA's Interest & Investment Income at -$247000.0 in Q1 2026, $115000.0 in Q4 2025, and $123000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 48.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 35.58 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 27.90 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 5.13 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 28.14 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Savara | 1.11 Bn | 1.11 Bn | - | -34,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -34,000.00 |
| Mar 31, 2026 | -247,000.00 |
| Dec 31, 2025 | 115,000.00 |
| Sep 30, 2025 | 123,000.00 |
| Jun 30, 2025 | -86,000.00 |
| Mar 31, 2025 | -154,000.00 |
| Dec 31, 2024 | -263,000.00 |
| Sep 30, 2024 | 583,000.00 |
| Jun 30, 2024 | -25,000.00 |
| Mar 31, 2024 | -251,000.00 |
| Dec 31, 2023 | 252,000.00 |
| Sep 30, 2023 | -5,000.00 |
| Jun 30, 2023 | -60,000.00 |
| Mar 31, 2023 | 14,000.00 |
| Dec 31, 2022 | 29,000.00 |
| Sep 30, 2022 | 77,000.00 |
| Jun 30, 2022 | 20,000.00 |
| Mar 31, 2022 | -88,000.00 |
| Dec 31, 2021 | -38,000.00 |
| Sep 30, 2021 | -10,000.00 |